Bjorn Nilsson Appointed as New President for Karo Bio

Apr 25, 2001, 01:00 ET from Karo Bio

    Huddinge, Sweden, April 25 /PRNewswire/ -- Karo Bio's Board of Directors
 has recruited Bjorn O. Nilsson to become the new President for the company
 succeeding Torben Jorgensen who left the company on the 23rd of April 2001.
 Until now Bjorn Nilsson has been Head of Research at Amersham Pharmacia
 Biotech AB in Uppsala.  The Board has also appointed Per Otteskog, Senior Vice
 President Investor Relations, as acting President.  The exact time for Bjorn
 Nilsson's start at Karo Bio has not been determined but it will take place
 within three months.
 
     -- "Karo Bio has made substantial progress with new business agreements
        and research progress.  To secure that the company continues to develop
        its full potential the Board decided to recruit a new President with a
        strong research background," says Per-Olof Martensson, Chairman at Karo
        Bio.
 
     -- "We are very happy to bring Bjorn Nilsson to the company and the Board
        is convinced that with his considerable experience, he can immediately
        contribute to Karo Bio's growth," says Per-Olof Martensson.
 
     Bjorn Nilsson, 45 years old, has a long and broad experience from the
 pharmaceutical and biotechnology industry, primarily through his career at
 Genentech USA 1986-1988 and within the Pharmacia group and Amersham Pharmacia
 Biotech (AP Biotech).  He has served as head of Biology within Pharmacia &
 Upjohn, Sweden up to 1997 and presently as Head of Research at AP Biotech AB
 in Uppsala.  Today Bjorn Nilsson leads a successful organization of 270
 scientists in Uppsala and Tokyo.
     Besides these leading industry positions Bjorn Nilsson has a strong
 research background.  He is Associate Professor in Biochemistry at the Royal
 Institute of Technology and has been a member of the Royal Swedish Academy of
 Engineering Sciences, IVA, since 1996.  This year he became Vice Chairman for
 the Biotechnology section.
     "I have followed the development of Karo Bio for a long time.  It is a
 very exciting company that is well positioned for future drug discovery.  I am
 very enthusiastic about leading the company in its further development," says
 Bjorn Nilsson.
 
     A curriculum for Bjorn O. Nilsson ends this press release.
 
     April, 2001
 
     Curriculum vitae
 
     Bjorn Olof Nilsson
 
 
     Present Position
     Global Vice President Protein Area R&D
     Vice President R&D, Sweden
     Amersham Pharmacia Biotech AB
     SE-751 84 Uppsala, Sweden
 
     Associate Adjunct Professor in Biochemistry
     Royal Institute of Technology
     Department of Biochemistry & Biotechnology
     SE-100 44 Stockholm, Sweden
 
     Post Graduate Education
     September 1976 - September 1981
     Royal Institute of Technology (RIT, Swedish: KTH), Stockholm, Sweden
     Degree: Master of Science in Chemistry; Swedish: Civ.Ing. i Kemi
     February 1982 - October 1986
     RIT Graduate school, Dept of Biochemistry, Stockholm, Sweden
     Degree: Ph.D. in Biochemistry; Swedish: Tekn. D. i Biokemi
     October 1986 - October 1988
     Post-Doctoral Research Fellowship at Genentech, Inc., Dept of Protein
     Engineering, South San Francisco, USA
 
     Positions held since 1986
     Oct. 1986 - Oct. 1988    Post-Doctoral Research Fellow, Department
                              of Protein Engineering, Genentech, Inc.,
                              South San Francisco, USA
     Nov. 1988 - May 1990     Assistant Professor at RIT (Dept of
                              Biochemistry), Stockholm, Sweden
     May 1990 - May 1991      Scientist, Kabi Pharmacia, BioScience Center,
                              Stockholm, Sweden
     May 1990 -               Adjunct Associate Professor, RIT, Dept of
                              Biochemistry, Stockholm, Sweden
     May 1991 - June 1992     Senior Scientist, Kabi Pharmacia BioScience
                              Center, Stockholm, Sweden
     June 1992 - October 1996 Head of Structural Biochemistry, Pharmacia
                              Biopharmaceuticals, Stockholm, Sweden
     October 1996 -Dec. 1997  Director of Biology Research, Pharmacia & Upjohn
                              AB, Stockholm, Sweden
     Jan. 1998 -              Global Vice President, Protein Area R&D,
                              Vice President R&D Sweden, Amersham Pharmacia
                              Biotech, SE-751 84 Uppsala, Sweden
 
 
     Bibliography
     Ph.D. Thesis entitled "Fusions to the gene encoding staphylococcal protein
     A"  (RIT, Stockholm, 1986, ISBN 91-7170-997-5), 63 full scientific papers
     and 8 patents / patent applications. Complete listing is provided below.
 
     Recognition Awards ($)
     Post-Doc Fellowship award from the Swedish Research Council of Engineering
     Sciences (TFR) (1986-1988) Genentech Recognition Award (1988)
     Pharmacia & Upjohn Science and Medicine Award (1996)
 
     Selected External Assignments in Recent Five Years
     Ongoing
     Adjunct Associate Professorship, Department of Biochemistry, RIT
     (May 1990 -)
     Chairman of the Board of the Structural Biology Program of the Swedish
      Strategic Research Foundation (1996-)
     Elected as a full member of Section X (Biotechnology) of the Royal Swedish
      Academy of Engineering Sciences (1996-)
     Member of the Board of the National Committee for Biophysics (branch of
      the Swedish Royal Academy of Sciences) (1996-)
     Member of the Board of the Nanochemistry Program of the Swedish Strategic
      Research Foundation (1998-)
     Member of the Evaluating Committee of the Biotechnology Program of the
      Swedish Research Council of Engineering Sciences (TFR) (1998-)
     Member of the Board of BioInvent (Lund, Sweden) (1999-)
     Member of the Board of the Wallenberg Foundation Functional Genomics
      Program North (2000-)
     Member of the Selection Committee for Strategic Research Centers of the
      Swedish Strategic Research Foundation (2001-)
     Deputy Chairman of Section X (Biotechnology) of the Royal Swedish Academy
      of Engineering Sciences (2001-)
 
     Completed
     Member of the Medical BioScience Committee of the Swedish Strategic
      Research Foundation (1994-1996)
     Member of NUTEK investigation committee BoTiS ("Biologi och Teknik i
      Samverkan") (1994)
     Member of the Structural Biology National Planning Group of the Swedish
      Strategic Research Foundation (1994)
     Faculty Ph.D. opponent twice (1994)
     Scientific organizer of the Scheele Symposium (November 1994)
     Chairman of the Molecular Recognition National Planning Group of the
      Swedish Strategic Research Foundation (1995)
     Expert evaluator of candidate for the Nobel Price Committee (Chemistry
      Price) (1995)
     Expert evaluator of the European Commission for the IV framework program
     (Biotechnology) (1996)
     Member of the Industrial Research Group of the Royal Swedish Academy of
      Engineering Sciences (1995-1997)
     Member of the Board of the Swedish Chemical Society ("Kemistsamfundet"),
      Stockholm Division (1993-1997)
     Member of Board of the Department of Biochemistry at the Royal Institute
      of Technology (RIT; KTH) in Stockholm (1994-1997)
     Member of the Medicinal Chemistry Committee of the Swedish Pharmaceutical
      Society (1996-1998)
     Member of the Board of the European Synchrotron Research Facility (ESRF)
      Committee f NFR (1994-1998)
     Member of the Board of the Stockholm Biomedical Graduate School Program of
      the Swedish Strategic Research Foundation (1996-1999)
     Participant of the Royal Technology Mission to Canada 1999, Headed by HM
      King Carl XVI Gustaf
     Member of "IVA 2000," a working group within the Royal Swedish Academy of
      Engineering Sciences for the re-engineering of the organisation (2000)
 
     Memberships
     Member of the American Association for the Advancement of Sciences (AAAS)
     (1986-)
     Member of the Protein Society (1988-)
     Member of the Swedish Chemical Society ("Kemistsamfundet") (1992-)
     Member of the Swedish Pharmaceutical Society ("Apotekarsocieteten")(1995-)
 
     Huddinge, April 25, 2001
     KARO BIO AB (publ)
 
     For further information, please contact:
     Karo Bio
     Per-Olof Martensson
     Chairman Karo Bio AB
     Direct: +46-8-608 60 20
     Cell phone: +46-709-415400
 
     Background
 
     Karo Bio is a company with operations in the United States and Sweden. The
 Company employs 120 people and has 250 patent cases including 100 approved
 patents.
     Karo Bio has been listed on the Stockholm stock exchange (KARO) since 1998
 and has a leading position in the field of drug discovery and nuclear
 receptors.  Nuclear receptors are important and validated drug targets for a
 number of clinical indications and the Company uses proprietary technologies
 for the development of novel and improved therapies for major markets.  An
 important base for generation of new therapeutic strategies is Karo Bio's
 strong academic network.
     Karo Bio has drug discovery programs in therapeutic areas such as women's
 health care, metabolic disorders, cardiovascular disease, diabetes,
 dermatology, ophthalmology and infectious disease.
     Karo Bio collaborates with major pharmaceutical companies for development
 of products through clinical trials and marketing.  In these partnerships Karo
 Bio receives downpayments, R&D funding and royalties on net sales when
 products reach the market.
     Karo Bio's product pipeline is strong and includes a number of proprietary
 projects that which will be partnered in different stages.  Karo Bio generally
 collaborates with major pharmaceutical companies from early drug discovery
 through clinical trials but also takes the opportunity to bring products to
 the clinic before partnering.  Apart from financial compensations the partners
 bring competence and resources for drug development and marketing to the
 collaboration.
     Karo Bio has one product in clinical trials and expects to enter clinical
 trials with partners in the future.
     Karo Bio has a strong financial position and it's partnerships include
 Abbott Laboratories, Bristol-Myers Squibb, Merck & Co., Aventis Pharma, Bayer
 AG, Boehringer Ingelheim Pharmaceuticals, Inc. GPC Biotech, NovImmune S.A.,
 and Serono International S.A.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X33632431
 
 

SOURCE Karo Bio
    Huddinge, Sweden, April 25 /PRNewswire/ -- Karo Bio's Board of Directors
 has recruited Bjorn O. Nilsson to become the new President for the company
 succeeding Torben Jorgensen who left the company on the 23rd of April 2001.
 Until now Bjorn Nilsson has been Head of Research at Amersham Pharmacia
 Biotech AB in Uppsala.  The Board has also appointed Per Otteskog, Senior Vice
 President Investor Relations, as acting President.  The exact time for Bjorn
 Nilsson's start at Karo Bio has not been determined but it will take place
 within three months.
 
     -- "Karo Bio has made substantial progress with new business agreements
        and research progress.  To secure that the company continues to develop
        its full potential the Board decided to recruit a new President with a
        strong research background," says Per-Olof Martensson, Chairman at Karo
        Bio.
 
     -- "We are very happy to bring Bjorn Nilsson to the company and the Board
        is convinced that with his considerable experience, he can immediately
        contribute to Karo Bio's growth," says Per-Olof Martensson.
 
     Bjorn Nilsson, 45 years old, has a long and broad experience from the
 pharmaceutical and biotechnology industry, primarily through his career at
 Genentech USA 1986-1988 and within the Pharmacia group and Amersham Pharmacia
 Biotech (AP Biotech).  He has served as head of Biology within Pharmacia &
 Upjohn, Sweden up to 1997 and presently as Head of Research at AP Biotech AB
 in Uppsala.  Today Bjorn Nilsson leads a successful organization of 270
 scientists in Uppsala and Tokyo.
     Besides these leading industry positions Bjorn Nilsson has a strong
 research background.  He is Associate Professor in Biochemistry at the Royal
 Institute of Technology and has been a member of the Royal Swedish Academy of
 Engineering Sciences, IVA, since 1996.  This year he became Vice Chairman for
 the Biotechnology section.
     "I have followed the development of Karo Bio for a long time.  It is a
 very exciting company that is well positioned for future drug discovery.  I am
 very enthusiastic about leading the company in its further development," says
 Bjorn Nilsson.
 
     A curriculum for Bjorn O. Nilsson ends this press release.
 
     April, 2001
 
     Curriculum vitae
 
     Bjorn Olof Nilsson
 
 
     Present Position
     Global Vice President Protein Area R&D
     Vice President R&D, Sweden
     Amersham Pharmacia Biotech AB
     SE-751 84 Uppsala, Sweden
 
     Associate Adjunct Professor in Biochemistry
     Royal Institute of Technology
     Department of Biochemistry & Biotechnology
     SE-100 44 Stockholm, Sweden
 
     Post Graduate Education
     September 1976 - September 1981
     Royal Institute of Technology (RIT, Swedish: KTH), Stockholm, Sweden
     Degree: Master of Science in Chemistry; Swedish: Civ.Ing. i Kemi
     February 1982 - October 1986
     RIT Graduate school, Dept of Biochemistry, Stockholm, Sweden
     Degree: Ph.D. in Biochemistry; Swedish: Tekn. D. i Biokemi
     October 1986 - October 1988
     Post-Doctoral Research Fellowship at Genentech, Inc., Dept of Protein
     Engineering, South San Francisco, USA
 
     Positions held since 1986
     Oct. 1986 - Oct. 1988    Post-Doctoral Research Fellow, Department
                              of Protein Engineering, Genentech, Inc.,
                              South San Francisco, USA
     Nov. 1988 - May 1990     Assistant Professor at RIT (Dept of
                              Biochemistry), Stockholm, Sweden
     May 1990 - May 1991      Scientist, Kabi Pharmacia, BioScience Center,
                              Stockholm, Sweden
     May 1990 -               Adjunct Associate Professor, RIT, Dept of
                              Biochemistry, Stockholm, Sweden
     May 1991 - June 1992     Senior Scientist, Kabi Pharmacia BioScience
                              Center, Stockholm, Sweden
     June 1992 - October 1996 Head of Structural Biochemistry, Pharmacia
                              Biopharmaceuticals, Stockholm, Sweden
     October 1996 -Dec. 1997  Director of Biology Research, Pharmacia & Upjohn
                              AB, Stockholm, Sweden
     Jan. 1998 -              Global Vice President, Protein Area R&D,
                              Vice President R&D Sweden, Amersham Pharmacia
                              Biotech, SE-751 84 Uppsala, Sweden
 
 
     Bibliography
     Ph.D. Thesis entitled "Fusions to the gene encoding staphylococcal protein
     A"  (RIT, Stockholm, 1986, ISBN 91-7170-997-5), 63 full scientific papers
     and 8 patents / patent applications. Complete listing is provided below.
 
     Recognition Awards ($)
     Post-Doc Fellowship award from the Swedish Research Council of Engineering
     Sciences (TFR) (1986-1988) Genentech Recognition Award (1988)
     Pharmacia & Upjohn Science and Medicine Award (1996)
 
     Selected External Assignments in Recent Five Years
     Ongoing
     Adjunct Associate Professorship, Department of Biochemistry, RIT
     (May 1990 -)
     Chairman of the Board of the Structural Biology Program of the Swedish
      Strategic Research Foundation (1996-)
     Elected as a full member of Section X (Biotechnology) of the Royal Swedish
      Academy of Engineering Sciences (1996-)
     Member of the Board of the National Committee for Biophysics (branch of
      the Swedish Royal Academy of Sciences) (1996-)
     Member of the Board of the Nanochemistry Program of the Swedish Strategic
      Research Foundation (1998-)
     Member of the Evaluating Committee of the Biotechnology Program of the
      Swedish Research Council of Engineering Sciences (TFR) (1998-)
     Member of the Board of BioInvent (Lund, Sweden) (1999-)
     Member of the Board of the Wallenberg Foundation Functional Genomics
      Program North (2000-)
     Member of the Selection Committee for Strategic Research Centers of the
      Swedish Strategic Research Foundation (2001-)
     Deputy Chairman of Section X (Biotechnology) of the Royal Swedish Academy
      of Engineering Sciences (2001-)
 
     Completed
     Member of the Medical BioScience Committee of the Swedish Strategic
      Research Foundation (1994-1996)
     Member of NUTEK investigation committee BoTiS ("Biologi och Teknik i
      Samverkan") (1994)
     Member of the Structural Biology National Planning Group of the Swedish
      Strategic Research Foundation (1994)
     Faculty Ph.D. opponent twice (1994)
     Scientific organizer of the Scheele Symposium (November 1994)
     Chairman of the Molecular Recognition National Planning Group of the
      Swedish Strategic Research Foundation (1995)
     Expert evaluator of candidate for the Nobel Price Committee (Chemistry
      Price) (1995)
     Expert evaluator of the European Commission for the IV framework program
     (Biotechnology) (1996)
     Member of the Industrial Research Group of the Royal Swedish Academy of
      Engineering Sciences (1995-1997)
     Member of the Board of the Swedish Chemical Society ("Kemistsamfundet"),
      Stockholm Division (1993-1997)
     Member of Board of the Department of Biochemistry at the Royal Institute
      of Technology (RIT; KTH) in Stockholm (1994-1997)
     Member of the Medicinal Chemistry Committee of the Swedish Pharmaceutical
      Society (1996-1998)
     Member of the Board of the European Synchrotron Research Facility (ESRF)
      Committee f NFR (1994-1998)
     Member of the Board of the Stockholm Biomedical Graduate School Program of
      the Swedish Strategic Research Foundation (1996-1999)
     Participant of the Royal Technology Mission to Canada 1999, Headed by HM
      King Carl XVI Gustaf
     Member of "IVA 2000," a working group within the Royal Swedish Academy of
      Engineering Sciences for the re-engineering of the organisation (2000)
 
     Memberships
     Member of the American Association for the Advancement of Sciences (AAAS)
     (1986-)
     Member of the Protein Society (1988-)
     Member of the Swedish Chemical Society ("Kemistsamfundet") (1992-)
     Member of the Swedish Pharmaceutical Society ("Apotekarsocieteten")(1995-)
 
     Huddinge, April 25, 2001
     KARO BIO AB (publ)
 
     For further information, please contact:
     Karo Bio
     Per-Olof Martensson
     Chairman Karo Bio AB
     Direct: +46-8-608 60 20
     Cell phone: +46-709-415400
 
     Background
 
     Karo Bio is a company with operations in the United States and Sweden. The
 Company employs 120 people and has 250 patent cases including 100 approved
 patents.
     Karo Bio has been listed on the Stockholm stock exchange (KARO) since 1998
 and has a leading position in the field of drug discovery and nuclear
 receptors.  Nuclear receptors are important and validated drug targets for a
 number of clinical indications and the Company uses proprietary technologies
 for the development of novel and improved therapies for major markets.  An
 important base for generation of new therapeutic strategies is Karo Bio's
 strong academic network.
     Karo Bio has drug discovery programs in therapeutic areas such as women's
 health care, metabolic disorders, cardiovascular disease, diabetes,
 dermatology, ophthalmology and infectious disease.
     Karo Bio collaborates with major pharmaceutical companies for development
 of products through clinical trials and marketing.  In these partnerships Karo
 Bio receives downpayments, R&D funding and royalties on net sales when
 products reach the market.
     Karo Bio's product pipeline is strong and includes a number of proprietary
 projects that which will be partnered in different stages.  Karo Bio generally
 collaborates with major pharmaceutical companies from early drug discovery
 through clinical trials but also takes the opportunity to bring products to
 the clinic before partnering.  Apart from financial compensations the partners
 bring competence and resources for drug development and marketing to the
 collaboration.
     Karo Bio has one product in clinical trials and expects to enter clinical
 trials with partners in the future.
     Karo Bio has a strong financial position and it's partnerships include
 Abbott Laboratories, Bristol-Myers Squibb, Merck & Co., Aventis Pharma, Bayer
 AG, Boehringer Ingelheim Pharmaceuticals, Inc. GPC Biotech, NovImmune S.A.,
 and Serono International S.A.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X33632431
 
 SOURCE  Karo Bio